by Victoria Radke | Jul 19, 2021
The Food and Drug Administration (FDA) has approved belumosudil, a kinase inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of two or more prior lines of systemic therapy. cGVHD is a rare complication that can occur after a stem...
by Victoria Radke | Jul 1, 2021
The U.S. Food and Drug Administration (FDA) has approved Rylaze [asparaginase erwinia chrysanthemi (recombinant)-rywn)] as a component of chemotherapy for patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived...
by Victoria Radke | Jun 25, 2021
The U.S. Food and Drug Administration (FDA) has approved Santen Pharmaceutical’s cyclosporine ophthalmic emulsion 0.1% eye drops (Verkazia) for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. VKC is a rare and recurrent allergic eye...
by Victoria Radke | Jun 18, 2021
The U.S. Food and Drug Administration (FDA) has denied the approval of arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC). NPC is a disabling neurogenetic disorder that has been diagnosed prenatally, neonatally,...
by Victoria Radke | Jun 16, 2021
The U.S. Food and Drug Administration (FDA) has approved Blueprint Medicines’ avapritinib (brand name: Ayvakit) for the treatment of adult patients with advanced systemic mastocytosis (SM). Advanced SM is a rare, hematologic disorder most often caused by a...
